Jamie Stiff

Managing Director, Genesys Capital

Jamie Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in nine early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Past board affiliations include Allostera Pharma Inc., gIcare Pharma Inc., Interface Biologics, Inc., Matregen Corp, Naurex Inc. (acquired by Allergan NYSE:AGN), NeurAxon Inc., StemPath Inc., Therapeutic Monitoring Systems Inc. and Zelos Therapeutics Inc. Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.